ArticleResearch in pharmaceutical sciences2021
Design of a chitosan-based nano vaccine against epsilon toxin of
Article in Research in pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
- Protective antigens hidden in the bovine Clostridium vaccine.Frontiers in immunology · 2026Article
- The efficacy of egg albumin nanoparticles adjuvanted Clostridium perfringens type D toxoid vaccine in rabbits.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Effect ofNAM journal · 2025Article
- Current status of nano-vaccinology in veterinary medicine science.Veterinary medicine and science · 2023Review
- A comparative study of the arazyme-based fusion proteins with various ligands for more effective targeting cancer therapy: anResearch in pharmaceutical sciences · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeEXPERIMENTAL APPROACH: The FINDINGS/
resultsThe results of ELISA showed that IgA antibody serum level increased sufficiently using recombinant protein with nanoparticle as an oral and injectable formulation. IgG antibody titers increased significantly after administrating the recombinant proteins with nanoparticles through both oral delivery and intravenous injection. CONCLUSION AND IMPLICATION: In conclusion, the recombinant ETX is suggested as a good candidate for vaccine production against diseases caused by ETX of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.